Rösch AG Medizintechnik
Rösch AG Medizintechnik english

Rösch AG: Extension of Management Board and re-orientation of core business Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Rösch AG: Extension of Management Board and re-orientation of core business Rösch AG Medizintechnik (SIN 529 140), Berlin, announces that the Supervisory Board has appointed Prof Dr med Burghard Weidler to the Management Board with the beginning of November 1, 2001. Prof Weidler has 17 years management experience in the pharma and health care industry in the areas of research and development, marketing and sales as well as strategic co-operations. Most recently Prof Weidler was on the Management Board of Fresenius Kabi AG. Prof Weidler will manage the extended business area “Needle-free injection and monitoring systems” which represents Rösch AG’s core business. Among his main responsibilities are the closing of development and sales co-operations with the pharma industry in the context of a strategic and structural re-orientation of the company, and in addition to the approval by health insurance companies of the needle-free injection system INJEX(tm) in Germany also its global launch. Prof Weidler already participated in negotiations with potential sales partners in the pharma industry, thus satisfying himself as to the chances of the needle- free injection and monitoring systems. The strong performance with regard to development at Rösch AG and the great variety of different development projects provide a very important basis for the realisation of co-operations. Furthermore the Supervisory Board has placed the authorisation for a share buy- back programme on the agenda of the Annual General Meeting to be held December 4, 2001. The Management Board Further information can be obtained from: Rösch AG Medizintechnik Buckower Damm 114, 12349 Berlin Tel. +49 (30) 66791537 e-mail: vorstand@roesch-ag.de end of ad-hoc-announcement (c)DGAP 23.10.2001 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: Both the Supervisory Board and the Management Board are satisfied that the appointment of Prof Dr med B. Weidler to the Management Board and the clear focus on the core business of “needle-free injection and monitoring systems” are the best conditions for a successful placement of the products on the market. Prof Weidler will utilise his extensive management experience, especially at Fresenius Kabi, to adjust the structures in the core business area such that the strategic re-orientation rapidly shows results. Prof Weidler already analysed the company as a consultant and prepared several prerequisites for rapid implementation in co-operation with the Management Board. The direct sales and marketing activities for the placement of the INJEX(tm) system on the diabetes market have already been significantly reduced. The cost risk has thus been considerably minimised and negotiations with renowned insulin producers will continue in order to successfully place the INJEX(tm) system on the diabetes market in co-operations. Together with insulin INJEX(tm) is particularly suitable for Type II diabetics converting from tablets needle-free to insulin. This is attractive for the producers of insulin to realise higher sales and increase their market share. For cost reasons timely conversion to insulin is very important for the health insurance companies as the known side- effects otherwise result in high treatment costs. Health insurance approval in Germany could significantly assist this co- operation with insulin producers. The excellent research and development work at Rösch AG offers approaches to solutions for many different drugs as well as for other dosages and for drugs with pre-filled disposable ampoules. This can be utilised as a decisive advantage over competitors and, under the management of Prof Weidler, can lead to important contracts in the pharma and biotech industries. Prof Weidler is already involved in ongoing negotiations, particularly regarding insulin, heparin (thrombosis prevention), interferon (multiple sclerosis) and interleukin. The Annual Report for the 2000/2001 financial year is to available in the company and placed on the internet on October 24, 2001. The accounts press conference is scheduled for 10.30 a.m. on November 6, in Frankfurt. ——————————————————————————– WKN: 529 140; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Stuttgart, Hannover 230829 Okt 01